Renalytix PLC Director/PDMR Shareholding (8886K)
07 September 2021 - 1:33AM
UK Regulatory
TIDMRENX
RNS Number : 8886K
Renalytix PLC
06 September 2021
Renalytix plc
("Renalytix" or the "Company")
Director/PDMR Dealing
New York, 6 September 2021 - Renalytix (LSE: RENX) announces
that it has been advised of the sale by O. James Sterling, the
Company's Chief Financial Officer, of 3,000 American Depositary
Shares ("ADS"), each representing two ordinary shares of GBP0.0025
each in the capital of the Company ("Ordinary Shares"), under a
Rule 10b5-1 trading plan established in accordance with Rule 10b5-1
under the U.S. Securities Exchange Act of 1934, as amended, and the
EU Market Abuse Regulation as it forms part of UK law by virtue of
the European Union (Withdrawal) Act 2018 ("MAR").
Rule 10b5-1 plans permit directors, officers and other company
insiders to adopt, at times when they are not in possession of
material, non-public information, or inside information, written
plans for trading securities in a non-discretionary, pre-scheduled
manner in the future.
Following completion of the sale, O. James Sterling is
interested in 1,805,236 Ordinary Shares representing 2.50% of the
current issued share capital of the Company.
For further information, please contact:
Renalytix plc www.renalytix.com
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker) Tel: 020 7710 7600
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker) Tel: 020 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303
About Kidney Disease
Kidney disease is now recognized as a public health epidemic
affecting over 850 million people globally. The Centers for Disease
Control and Prevention (CDC) estimates that 15% of US adults, or 37
million people, currently have chronic kidney disease (CKD).
Further, the CDC reports that 9 out of 10 adults with CKD do not
know they have it and 1 out of 2 people with very low kidney
function who are not on dialysis do not know they have CKD*. Kidney
disease is referred to as a "silent killer" because it often has no
symptoms and can go undetected until a very advanced stage. Each
year kidney disease kills more people than breast and prostate
cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.
* https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html
About RenalytixAI
RenalytixAI is a developer of artificial intelligence-enabled
clinical in vitro diagnostic solutions for kidney disease, one of
the most common and costly chronic medical conditions globally.
RenalytixAI's products are being designed to make significant
improvements in kidney disease diagnosis, transplant management,
clinical care, patient stratification for drug clinical trials, and
drug target discovery. For more information, visit
www.renalytixai.com
The information contained in this notification is disclosed in
accordance with the requirements of MAR.
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name O. James Sterling
----------------------------- -------------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------
a) Position/status Chief Financial Officer
----------------------------- -------------------------------------------
b) Initial notification Initial Notification
/Amendment
----------------------------- -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------
a) Name Renalytix plc
----------------------------- -------------------------------------------
b) Legal Entity Identifier 213800NTOH3FK3WER551
----------------------------- -------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------------
a) Description of ADS', each ADS representing two Ordinary
the financial instrument, Shares of GBP0.0025 each.
type of instrument
Identification US75973T1016
code
----------------------------- -------------------------------------------
b) Nature of the transaction Sale of ADS' under a 10b5-1 trading plan
----------------------------- -------------------------------------------
c) Currency US Dollar
----------------------------- -------------------------------------------
d) Price(s) and volume(s) Price(s) Volume(s)
----------------------------- ---------------- -------------------------
$ 28.888170001 3,000 ADS (representing
6,000 Ordinary Shares)
----------------------------- ---------------- -------------------------
e) Aggregated information
- Aggregated volume 3,000 ADS (representing 6,000 Ordinary
- Price Shares)
- Aggregated total $ 28.888170001
$86,664.51
----------------------------- -------------------------------------------
f) Date of the transaction 31 August 2021
----------------------------- -------------------------------------------
g) Place of the transaction Nasdaq Stock Exchange
----------------------------- -------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHEASNKEDAFEFA
(END) Dow Jones Newswires
September 06, 2021 11:33 ET (15:33 GMT)
Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2024 to May 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2023 to May 2024